Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, randomized, controlled study to compare palonosetron plus dexamethasone before chemotherapy administration versus the same regimen on day one with dexamethasone continuing on days two and three in preventing nausea and vomiting in patients with solid tumors treated with moderately emetogenic chemotherapy

Trial Profile

Multicenter, randomized, controlled study to compare palonosetron plus dexamethasone before chemotherapy administration versus the same regimen on day one with dexamethasone continuing on days two and three in preventing nausea and vomiting in patients with solid tumors treated with moderately emetogenic chemotherapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Sep 2011

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Palonosetron (Primary) ; Dexamethasone; Dexamethasone
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use

Most Recent Events

  • 01 Aug 2011 Results published in Supportive Care in Cancer.
  • 02 Jun 2011 Primary endpoint 'Complete-control-of-nausea-and-vomiting' has been met.
  • 02 Jun 2011 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top